Atossa TherapeuticsATOS -1.61%26 EV-to-EBITDA is 0.18 as of Jul. 09, 2026, which is 65% below its 10-year median of 0.52. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 392 Biotechnology companies, Atossa Therapeutics ranks better than 93.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Atossa Therapeutics's enterprise value is $-7.28 Mil.
Atossa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.58 Mil. Therefore, Atossa Therapeutics's EV-to-EBITDA for today is 0.18.
The historical rank and industry rank for Atossa Therapeutics's EV-to-EBITDA or its related term are showing as below:
ATOS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.94 Med: 0.52 Max: 0.56
Current: 0.18
During the past 13 years, the highest EV-to-EBITDA of Atossa Therapeutics was 0.56. The lowest was -0.94. And the median was 0.52.
ATOS's EV-to-EBITDA is ranked better than 93.62% of 392
companies
in the Biotechnology industry
Industry Median: 12.965
vs ATOS: 0.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atossa Therapeutics's PE Ratio (TTM) for today is calculated as:
Atossa Therapeutics's share price for today is $2.45.
Atossa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Atossa Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atossa Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's EV-to-EBITDA falls into.
Atossa Therapeutics's current Enterprise Value is $-7.28 Mil.
Atossa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atossa Therapeutics (ATOS) has a EV-to-EBITDA of 0.18 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Atossa Therapeutics. This is 65% below median its historical median of 0.52. According to the industry distribution chart, Atossa Therapeutics ranks #25 out of 392 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Atossa Therapeutics' EV-to-EBITDA too high?
Atossa Therapeutics' current EV-to-EBITDA of 0.18 is 65% below median its 10-year median of 0.52. The Biotechnology industry median EV-to-EBITDA is 12.97. Atossa Therapeutics' value of 0.18 is 98.6% below this industry median. Based on the distribution chart, Atossa Therapeutics ranks #25 out of 392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' EV-to-EBITDA compare to QNCX and ZIVO?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #25 out of 392 companies for EV-to-EBITDA. This places Atossa Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.97. Atossa Therapeutics' value of 0.18 is 98.6% below this benchmark. While the company's 10-year median is 0.52 vs. the industry median of 12.97, Atossa Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.97, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atossa Therapeutics's current EV-to-EBITDA of 0.18 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Atossa Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current EV-to-EBITDA is 0.18, which is 65% below median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current EV-to-EBITDA of 0.18. The current EV-to-EBITDA is 0.18, which is 65% below median its 10-year median of 0.52 and 98.6% below the Biotechnology industry median of 12.97. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current EV-to-EBITDA is 0.18 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score
Get the complete analysis for ATOS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATOS has been successfully added to your 
